Completed PHASE3 INTERVENTIONAL 3-arm NCT01545076

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study

Sponsor: CSL Behring

Conditions Chronic Inflammatory Demyelinating Polyneuropathy Polyradiculoneuropathy

Interventions IgPro10 IgPro20 (high dose) IgPro20 (low dose) Placebo

Updated 9 times since 2017 Last updated: Jul 3, 2018 Started: Mar 31, 2012 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Inflammatory Demyelinating Polyneuropathy and Polyradiculoneuropathy, this trial is completed. The trial is conducted by CSL Behring and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Oct 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Oct 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring
ICON Clinical Research

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Aomori, Japan , Barcelona, Spain , Berlin, Germany , Birmingham, United States , Bochum, Germany , Centennial, United States , Charlotte, United States , Charlottesville, United States , Chiba, Japan and 66 more locations